Table 1.
Human papillomavirus (HPV) status in relation to oropharyngeal squamous cell carcinoma (OPSCC).
| Time interval of collected data | Samples | Men/women | Median Age | HPV genotypes | Detection method | HPV + rate | References | |
|---|---|---|---|---|---|---|---|---|
| China | ||||||||
| 2012–2018 | 49 | 29/20 | 53 | 16, 18, 52 | HPV 16/18 RNA ISH | 28.6% | Yang et al. (2020) | |
| 2007–2019 | 152 | 127/25 | NA | 11, 16, 18, 33, 53, 58 | HPV genotyping | 65.1% | Xu et al. (2020c) | |
| 2014–2019 | 257 | 221/36 | 60 | NA | HPV Genotyping | 18.3% | Xu et al. (2020b) | |
| 1999–2013 | 300 | 273/27 | 54 | 16, 33, 35, 56, 58, 68 | HPV Genotyping and/or p16 IHC | 25.0% | Chen et al. (2020) | |
| USA | ||||||||
| 2010–2014 | 1168 | 926/242 | 61 | NA | HPV 16/18 DNA ISH and/or p16 IHC | 52.8% | White et al. (2020) | |
| 2010–2016 | 45,940 | 38,0381/7902 | 60 | 16, 18, 31, 33, 35, 36, 45, 51, 52, 56, 58, 59, 68, 26, 53, 66, 67, 69, 70, 73, 82, 85 | HPV 16/18 DNA ISH and/or p16 IHC | 67.5% | Rotsides et al. (2020) | |
| 1996–2013 | 115 | 101/14 | 56 | NA | p16 IHC | 90.4% | Altenhofen et al. (2020) | |
| NA | 381 | 332/49 | NA | NA | HPV RNA | 79.8% | Liu et al. (2020) | |
| 2002–2013 | 611 | 517/94 | NA | NA | HPV ISH and p16 IHC | 89.0% | Elhalawani et al. (2020) | |
| 2007–2018 | 88 | 69/19 | 73 | 16, 18, 33, 35 | PCR amplification of HPV gene loci or p16 IHC | 70.5% | Dickstein et al. (2020) | |
| UK | ||||||||
| 2010–2016 | 273 | 207/66 | 59 | NA | p16 IHC | 73.3% | De Felice et al. (2020) | |
| Canada | ||||||||
| 2005–2017 | 2039 | 1668/371 | NA | NA | p16-IHC | 48.7% | Huang et al. (2020) | |
| 1997–2015 | 372 | 0/372a | NA | NA | p16-IHC | 56.8% | Gazzaz et al. (2019) | |
| 1998–2004 | 525 | 381/144 | NA | NA | p16-IHC, HPV DNA ISH | 73.5% | Hall et al. (2019) | |
| Australia | ||||||||
| 2016–2017 | 650 | 284/366 | 52 | 16 | HPV16 DNA | 1.8% | Tang et al. (2020) | |
| 2018–2019 | 910 | 315/595 | 37 | 13, 16, 18, 32 | HPV DNA | 35.3% | Jamieson et al. (2020) | |
| Australia and New Zealand | ||||||||
| NA | 189 | NA | NA | 16, 18 | P16 IHC and HPVRNA ISH | 88.1% | Young et al. (2020a, 2020b) | |
| Netherlands | ||||||||
| 2009–2016 | 216 | 143/73 | NA | NA | p16 IHC and HPV DNA | 31.9% | Chargi et al. (2020) | |
| 1995–2015 | 168 | 135/33 | NA | NA | p16 IHC and/or HPV DNA | 50.0% | Molony et al. (2020) | |
| Brazil | ||||||||
| 1999–2010 | 346 | 308/38 | 55 | 16 | HPV16 and p16 IHC | 6.1% | Buexm et al. (2020) | |
| 2017–2019 | 91 | 78/13 | 61 | NA | p16 IHC | 20.9% | Girardi et al. (2020) | |
| 1984–2014 | 215 | 190/25 | 56 | 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 | HPV DNA detection and/or p16 IHC | 59.1% | De Cicco et al. (2020) | |
| Germany | ||||||||
| 2000–2017 | 102 | 82/20 | 57.5 | 16, 18, 33, 59 | HPV genotyping and p16 IHC | 40.2% | Weiss et al. (2020) | |
| 2000–2011 | 141 | 103/38 | NA | 16 | HPV DNA and p16 IHC | 34.0% | Huebbers et al. (2019) | |
| 2000–2014 | 323 | 245/78 | 58.87 | NA | HPV DNA and p16 IHC | 19.8% | Grønhøj et al. (2019a) | |
| 2000–2017 | 730 | NA | NA | NA | HPV DNA and p16 IHC | 27.1% | Wittekindt et al. (2019) | |
| 2007–2016 | 92 | 77/15 | NA | 16, 18 | HPV Genotyping and p16 IHC | 71.4% | Freitag et al. (2020) | |
| Denmark | ||||||||
| 2000–2017 | 2169 | 1564/605 | 58 | 16, 18, 33, 25, 59, 26, 31, 45, 56, 11, 58 | HPV DNA detection and p16 IHC | 55.0% | Zamani et al. (2020) | |
| 2000–2014 | 417 | 0/417 | 61.2 | NA | HPV DNA and p16 IHC | 48.7% | Christensen et al. (2019) | |
| 2000–2014 | 993 | 720/273 | 59.50 | NA | HPV DNA and p16 IHC | 56.9% | Grønhøj et al. (2019a) | |
| 2000–2014 | 1499 | NA | NA | NA | HPV DNA and p16 IHC | 55.0% | Grønhøj et al. (2019b) | |
| 2000–2014 | 1243 | 903/340 | 60.2 | NA | HPV DNA and p16 IHC | 63.4% | Rasmussen et al. (2019) | |
| Korea | ||||||||
| NA | 60 | 50/10 | 59 | NA | HPV DNA detection and p16 IHC | 80.0% | Suh et al. (2020) | |
| 2004–2013 | 113 | 101/12 | NA | NA | HPV Genotyping and p16 IHC | 69.9% | Kwon et al. (2020) | |
| Austria | ||||||||
| 2014–2019 | 62 | 48/14 | NA | 16, 18, 33, 40, 62, 68 | HPV Genotyping or p16 IHC | 100% | Kofler et al. (2020) | |
| South Glasgow | ||||||||
| 2010–2017 | 272 | NA | NA | 16. 18. 33. 39. 58 | HPV Genotyping | 44.0% | Zubair et al. (2020) | |
| Finland | ||||||||
| 2000–2016 | 157 | 110/47 | 59.5 | NA | p16 IHC | 9.8% | Sievert et al. (2020) | |
| Spain | ||||||||
| 2017–2019 | 54 | 43/11 | 62 | NA | p16 IHC and HPV DNA | 18.5% | Viros Porcuna et al. (2020) | |
| Cameroon | ||||||||
| 2014–2015 | 101 | 31/70 | 42 | 32, 68, 82 | p16 IHC and HPV RNA ISH | 5.0% | Rettig et al. (2019) | |
| Sweden | ||||||||
| 2000–2018 | 195 | 123/72 | 67 | NA | HPV DNA and p16 IHC | 15.9% | Hammarstedt et al. (2020) | |
| Croatia | ||||||||
| 2002–2015 | 99 | 82/17 | 60 | NA | HPV DNA and HPV E6 mRNA | 40.4% | Božinović et al. (2019) | |
| Thailand | ||||||||
| 2010–2016 | 110 | 95/15 | 59 | 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82 | p16 IHC and HPV DNA ISH | 14.5% | Nopmaneepaisarn et al. (2019) | |
| Italy | ||||||||
| 2010–2017 | 59 | 43/16 | 66 | NA | HPV DNA | 41.2% | Ravanelli et al. (2020) |
Studies included in this table meet the following criteria: OPSCC patients; HPV DNA or RNA positive or p16 positive; studies published between January 2019 and October 2020
aThis study included women with OPSCC only
IHC: immunohistochemical staining; ISH: in situ hybridization